OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET

WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a conference call on Wednesday, August 12, 2026, at 4:30 p.m.

GlobeNewsWire • Jul 29, 2026

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer.

GlobeNewsWire • Jul 23, 2026

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest

GlobeNewsWire • Jun 30, 2026

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts

GlobeNewsWire • Jun 25, 2026

OptimizeRx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:

GlobeNewsWire • Jun 1, 2026

OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?

OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.

Zacks Investment Research • May 28, 2026

DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network

Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers

GlobeNewsWire • May 21, 2026

OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds

OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.

Zacks Investment Research • May 20, 2026

OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?

OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.

Zacks Investment Research • May 20, 2026

OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?

OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures. Revenues are now expected to be between $95 million and $100 million, compared with the previous range of $109-$114 million.

Zacks Investment Research • May 15, 2026